At any given time, we are working on multiple opportunities across the discovery and development continuum. Each one has its own unique path to commercialization with a corresponding timeline.
AST-100 - CHEMICAL LIBRARY OF POTENTIAL DRUG AND DRUG DELIVERY CANDIDATES
Next Generation Chemistry Platform for CNS Diseases
We have licensed a series of patented 4-AP derivatives. Initial ADMET modeling data suggests the potential to reduce toxicity while advancing the efficacy for MS and other CNS diseases.
Through strategic partnership with 3rd Coast Therapeutics, we have licensed orally active small molecule drugs to stop the spread of cancer.
Revolutionary Antimetastatic Therapy
Innovative Nano and micro materials for Controlled Drug Delivery
Our joint venture with MesoDynamics markets engineered micron sized, silicate based material that controllably binds and releases drug agents.